Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

CRISPR could help doctors attack blood cancer without destroying healthy cells | ScienceDaily (opens in a new tab)

sciencedaily.com · 2026-09-25

Short answerEvidenceSource

Short answer

Mixed

Mixed.

2 claims go further than the study. One other point was not covered by the paper.

  • 2 supported
  • 2 overstated
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Two of five claims overstate the study. Two of five check out. One claim the study doesn't address.

  • 2 supported
  • 2 overstated
  • 1 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5OverstatedResearchers used CRISPR to remove CD33 from donor stem cells, potentially giving doctors a way to attack aggressive blood cancers without destroying the healthy cells patients need after a transplant.View evidenceHide evidence

Why this verdict

The abstract supports that donor HCT cells were CRISPR-Cas9 edited to delete CD33 and that the strategy was intended to permit later CD33-targeted therapy. However, the headline-level framing that this gives doctors a way to attack aggressive blood cancers without destroying needed healthy cells goes beyond the early-phase, single-arm safety/feasibility evidence. The paper profile supports engraftment and absence of prolonged high-grade cytopenias with GO in a subset, not established anti-cancer efficacy or definitive protection of healthy cells.

1

Study evidence

All 30 patients receiving trem-cel achieved neutrophil engraftment by day 28.30/30; median 10 days (95% CI 9–10)

“In this multicenter, phase 1/2a, open-label study, adult patients with AML/MDS with high relapse risk received trem-cel after myeloablative conditioning”
2

Study evidence

GO maintenance was administered to 19 trem-cel recipients in a phase 1 dose-escalation (n=15) and phase 2 expansion (n=4) framework.

“adult patients with AML/MDS with high relapse risk received trem-cel… followed by GO maintenance (0.5-2.0 mg m−2 day 1 per 28-day cycles).”
Claim 2 of 5OverstatedNineteen patients received at least one cycle of gemtuzumab ozogamicin, and across doses patients maintained their blood cell counts, suggesting the gene-edited transplant protected them from the severe drops in blood cells often seen after conventional transplantation.View evidenceHide evidence

As stated19 patients

Why this verdict

The profile supports that 19 patients received GO maintenance and that GO was tolerated up to 2 mg m−2 with no prolonged high-grade cytopenias observed. But saying patients 'maintained their blood cell counts' and that this suggests the transplant protected them from severe drops often seen after conventional transplantation adds causal and comparative force not established by the abstract-level evidence, especially given the small, open-label, single-arm subset and lack of detailed cytopenia data.

1

Study evidence

GO maintenance was administered to 19 trem-cel recipients in a phase 1 dose-escalation (n=15) and phase 2 expansion (n=4) framework.

“adult patients with AML/MDS with high relapse risk received trem-cel… followed by GO maintenance (0.5-2.0 mg m−2 day 1 per 28-day cycles).”
Claim 3 of 5Not coveredThe article says side effects were broadly similar to standard stem cell transplantation, and seven patients died during the study.View evidenceHide evidence

As stated7 deaths

Why this verdict

The abstract profile reports common adverse events as cytopenias and infections and three transplant-related deaths, but it does not provide full adverse-event rates, a comparison to standard stem cell transplantation, or total deaths from all causes. The claim that side effects were broadly similar to standard transplantation and that seven patients died may be in the full paper or article, but it is not verifiable from the abstract-depth profile supplied.

1

Study evidence

All 30 patients receiving trem-cel achieved neutrophil engraftment by day 28.30/30; median 10 days (95% CI 9–10)

“In this multicenter, phase 1/2a, open-label study, adult patients with AML/MDS with high relapse risk received trem-cel after myeloablative conditioning”
2

Study evidence

GO maintenance was administered to 19 trem-cel recipients in a phase 1 dose-escalation (n=15) and phase 2 expansion (n=4) framework.

“adult patients with AML/MDS with high relapse risk received trem-cel… followed by GO maintenance (0.5-2.0 mg m−2 day 1 per 28-day cycles).”
Claim 4 of 5SupportedIn a 30-patient trial, the edited cells successfully took hold and appeared to shield blood cells from a CD33-targeted cancer treatment.View evidenceHide evidence

As stated30 patients

Why this verdict

The profile reports a 30-patient phase 1/2a trial in which all 30 trem-cel recipients achieved neutrophil engraftment by day 28, supporting that the edited cells took hold. It also reports that 19 patients received GO maintenance and no prolonged high-grade cytopenias were observed, supporting the hedged statement that the approach appeared to shield blood cells from a CD33-targeted treatment, provided the GO finding is understood as applying to the 19-patient subset rather than all 30.

1

Study evidence

All 30 patients receiving trem-cel achieved neutrophil engraftment by day 28.30/30; median 10 days (95% CI 9–10)

“In this multicenter, phase 1/2a, open-label study, adult patients with AML/MDS with high relapse risk received trem-cel after myeloablative conditioning”
2

Study evidence

GO maintenance was administered to 19 trem-cel recipients in a phase 1 dose-escalation (n=15) and phase 2 expansion (n=4) framework.

“adult patients with AML/MDS with high relapse risk received trem-cel… followed by GO maintenance (0.5-2.0 mg m−2 day 1 per 28-day cycles).”
Claim 5 of 5SupportedThe study was a phase 1/2 multicenter trial in adults with AML or MDS at high risk of relapse, and all 30 patients achieved engraftment by day 28.View evidenceHide evidence

As stated30 adults; engraftment by day 28

Why this verdict

This matches the abstract profile: a multicenter phase 1/2a open-label trial in adults with AML/MDS at high relapse risk, with all 30 trem-cel recipients achieving neutrophil engraftment by day 28. The story omits the 'open-label' and 'phase 1/2a' details but does not materially alter this specific claim.

1

Study evidence

All 30 patients receiving trem-cel achieved neutrophil engraftment by day 28.30/30; median 10 days (95% CI 9–10)

“In this multicenter, phase 1/2a, open-label study, adult patients with AML/MDS with high relapse risk received trem-cel after myeloablative conditioning”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The study was single-arm and open-label, with no concurrent control group, limiting causal attribution and comparisons with conventional transplantation.

    This is an interpretation-changing limitation for claims that edited grafts protected cells or improved on conventional transplantation. The story’s caveats do not mention the absence of a control group or open-label design.

    From Phase 1/2a open-label multicenter interventional trial; Phase 1/2a open-label dose-escalation and dose-expansion mainten

  • The trial was stopped early, and the report includes the completed phase 1 portion, limiting planned phase 2 data and robustness of later outcomes.

    The profile identifies early stopping as a limitation. The story caveats listed funding, publication venue, therapy type, and deaths, but not early termination.

    From Phase 1/2a open-label multicenter interventional trial; Phase 1/2a open-label dose-escalation and dose-expansion mainten

  • The abstract does not report total survival estimates, follow-up duration, or total all-cause deaths; survival was only listed as a secondary endpoint.

    The story reports seven deaths, but that total is not available in the supplied abstract-depth profile. The lack of survival detail is material to interpreting mortality and clinical outcome claims.

    From Phase 1/2a open-label interventional cohort

  • The most common adverse events were cytopenias and infections, but the abstract does not provide frequencies, severity grades, denominators, or a direct comparison with standard transplantation.

    The story frames side effects as broadly similar to standard transplantation, but the supplied abstract profile lacks the comparative adverse-event detail needed for that statement and the caveats do not acknowledge this limitation.

    From Phase 1/2a open-label multicenter interventional trial; Phase 1/2a open-label dose-escalation and dose-expansion mainten

  • The percentage of CD33-negative myeloid cells was a prespecified secondary endpoint, but the abstract reports no quantitative results for this biological persistence/representation endpoint.

    The story discusses edited cells engrafting and future CD33-targeted therapy implications, but it does not indicate that the abstract-level profile lacks quantitative data on persistence or representation of CD33-negative myeloid cells.

    From Correlative biomarker/phenotypic analysis (secondary endpoint)

  • GO pharmacokinetics after trem-cel transplant was a prespecified secondary endpoint, but the abstract provides no PK results, sampling schedule, or assay details.

    The story does not discuss GO PK. This omission is not central to the main lay claims, but it is a material paper element present in the abstract profile and absent from the story coverage.

    From human in vivo

4 things the story did carry across
  • The study was an early-phase phase 1/2a, multicenter, open-label interventional trial of CRISPR-Cas9 CD33-deleted allogeneic HCT product in adults with high-relapse-risk AML/MDS.
  • All 30 trem-cel recipients achieved neutrophil engraftment by day 28, with median engraftment time of 10 days.
  • GO maintenance was evaluated only in a subset of 19 patients, with dose escalation/expansion; it was tolerated up to the recommended phase 2 dose and no prolonged high-grade cytopenias were observed.
  • Three transplant-related deaths were reported in the abstract, attributed to renal failure, sepsis, and sinusoidal obstruction syndrome.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

5

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoEvaluate safety and early feasibility of CRISPR-Cas9 CD33-deleted allogeneic HCT product (trem-cel) in high-relapse-risk AML/MDS, focusing on engraftment and transplant safety outcomes.Phase 1/2a open-label multicenter interventional trialExpand

In plain English

Phase 1/2a multicenter open-label trial of CRISPR-Cas9 CD33-deleted allogeneic HCT product (trem-cel) in adults with high-relapse-risk AML/MDS assessing primary safety endpoint of neutrophil engraftment by day 28 and key transplant safety outcomes; all 30 trem-cel recipients achieved neutrophil engraftment by day 28 (median 10 days, 95% CI 9–10). A subset (n=19) received post-transplant gemtuzumab ozogamicin (GO) maintenance (dose escalation and expansion); GO was tolerated up to the recommended phase 2 dose of 2 mg m-2 without prolonged high-grade cytopenias. Three transplant-related deaths were reported (renal failure, sepsis, sinusoidal obstruction syndrome).

Key findings

  • All 30 patients receiving trem-cel achieved neutrophil engraftment by day 28.30/30; median 10 days (95% CI 9–10)
  • Gemtuzumab ozogamicin (GO) maintenance was administered to 19 patients (15 in phase 1 dose escalation; 4 in phase 2 expansion) and was tolerated up to the recommended phase 2 dose of 2 mg m-2 without prolonged high-grade cytopenias.n=19 for GO-treated subset; RP2D reported as 2 mg m-2
“In this multicenter, phase 1/2a, open-label study, adult patients with AML/MDS with high relapse risk received trem-cel after myeloablative conditioning”
What this piece can’t prove
  • Trial was stopped early; this report includes the completed phase 1 portion (abstract indicates early termination).
  • GO maintenance safety and pharmacokinetic assessments apply to a small subset (n=19), limiting precision for those findings.

2 further details could not be confirmed from the summary.

2human in vivoEvaluate safety/tolerability of post-HCT gemtuzumab ozogamicin (GO) maintenance when used after trem-cel, including dose escalation/expansion and hematologic toxicity.Phase 1/2a open-label dose-escalation and dose-expansion maintenance studyExpand

In plain English

In a subset of trem-cel recipients (n=19) enrolled in a multicenter phase 1/2a trial, post-HCT gemtuzumab ozogamicin (GO) maintenance was given in a dose-escalation/expansion framework (0.5–2.0 mg m−2 day 1, every 28 days); GO was reported as tolerated up to the recommended phase 2 dose of 2 mg m−2 with no prolonged high-grade cytopenias observed, and the most common adverse events were cytopenias and infections.

Key findings

  • GO maintenance was administered to 19 trem-cel recipients in a phase 1 dose-escalation (n=15) and phase 2 expansion (n=4) framework.
  • GO was reported as safely tolerated up to the recommended phase 2 dose of 2 mg m−2.
“adult patients with AML/MDS with high relapse risk received trem-cel… followed by GO maintenance (0.5-2.0 mg m−2 day 1 per 28-day cycles).”
What this piece can’t prove
  • Small sample size for the GO maintenance subset (n=19) limits precision of safety estimates.
  • Early stopping of the trial and statement that this report includes the completed phase 1 portion limit availability of planned phase 2 data.
  • Open-label, early-phase design without a control arm limits attribution of adverse events specifically to GO versus transplant-related or disease-related causes.

1 further detail could not be confirmed from the summary.

3human in vivoCharacterize biological persistence/representation of CD33-negative myeloid cells after trem-cel transplantation.Correlative biomarker/phenotypic analysis (secondary endpoint)Expand

In plain English

The trial prespecified measurement of the percentage of CD33-negative myeloid cells as a secondary (correlative) endpoint following trem-cel transplantation; the abstract does not report any quantitative results, time-course data, or assay details for this endpoint.

Key findings

  • The percentage of CD33-negative myeloid cells was a prespecified secondary endpoint in trem-cel recipients, but the abstract reports no measurement results or summary statistics for this endpoint.
“secondary endpoints including… percentage of CD33-negative myeloid cells”
What this piece can’t prove
  • Without the full text or supplementary data, the biological persistence or longitudinal representation of CD33-negative myeloid cells cannot be evaluated.

2 further details could not be confirmed from the summary.

4human in vivoCharacterize pharmacokinetics (PK) of GO after trem-cel transplantation.Expand

In plain English

Pharmacokinetics (PK) of gemtuzumab ozogamicin (GO) after trem-cel transplantation was prespecified as an additional secondary endpoint for patients receiving trem-cel+GO (19 patients received GO maintenance). The abstract states PK was assessed but provides no PK methods, assay details, sampling timepoints, or PK parameter results.

Key findings

  • Pharmacokinetics of GO after trem-cel transplant was prespecified as an additional secondary endpoint for trem-cel+GO recipients; 19 patients received GO maintenance (15 in phase 1 dose escalation and 4 in phase 2 expansion). The abstract does not report PK parameter estimates, sampling schedules, or assay details.
“Patients receiving trem-cel and GO were assessed for the additional secondary endpoints of… pharmacokinetics of GO after trem-cel transplant.”
What this piece can’t prove
  • Only the abstract is available for this unit; no PK tables, figures, or methods sections are provided.
  • Small PK population implied (19 GO recipients) and early stopping of the trial reduce robustness of potential PK conclusions.

2 further details could not be confirmed from the summary.

5human in vivoDescribe preliminary clinical outcomes (for example survival) in this early-phase trial/cohort.Phase 1/2a open-label interventional cohortExpand

In plain English

Survival was prespecified as a secondary endpoint for recipients of trem-cel in this phase 1/2a trial, but the abstract does not provide any survival estimates or follow-up duration; therefore no preliminary survival outcome data are reported in the abstract.

Key findings

  • Survival was a prespecified secondary endpoint for trem-cel recipients, but no survival estimates or descriptive time-to-event results are reported in the abstract.
“secondary endpoints including… and survival.”
What this piece can’t prove
  • Early stopping of the trial and small number of patients receiving maintenance therapy limit interpretability and likely statistical power for survival endpoints.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 38 candidate papers

Candidate

Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33).

JCO Precision Oncology · 2025 · PubMed, Crossref

Tessa (opens in a new tab)Source (opens in a new tab)

And 32 more candidates considered.